The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: a compound； the use of said compound； a synthetic intermediate in the preparation of compounds of pharmaceutical interest； the use of the compound to prepare a binder of diagnostic and/or therapeutic interest； the use of the compound to prepare a metabolic modulator drug or a neuromodulator drug； a pharmaceutical composition containing the claimed peptide compound； and a therapeutic method. The claimed compound binds to and/or modulates the activity of cannabinoid (CB) receptors, particularly CB1 and/or CB2, and/or muscarinic receptors, and has proven to be extremely useful for modulating the respective systems. The claimed composition is useful for modulating metabolic function and/or for neuromodulation. In one embodiment, the claimed compound provides excellent neuroprotective and anticonvulsant results when administered orally to a mammal, and, in addition to other advantages and technical effects, does not entail the drawbacks arising from the use of cannabinoid substances such as cannabidiol, and provides a stronger therapeutic effect in a smaller dosage and with fewer side effects.
